A Phase 2 Clinical Study to Explore the Optimal Dosage/Administration of PM012 Tablet in Alzheimer's Disease

NCT ID: NCT05811000

Last Updated: 2023-04-18

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 312 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2020-11-27
• Study Completion Date: 2024-08-13

Brief Summary

To evaluate the safety and efficacy of PM012 tablets for Alzheimer's disease, dose-finding study will be performed on phase 2b, and the established dose will be used for the non-inferiority phase 3 trial to evaluate the investigational product's safety and efficacy: Double blind, randomized, active drug comparative, multi-center, parallel-group clinical trial

Detailed Description

This study is to establish an effective therapeutic dose in Korean patients with a mild degree of Alzheimer's disease, by comparing the safety and efficacy of the investigational product PM012 tablet administered to the 2,600 mg /day group, 3,900 mg /day group, and 5,200 mg /day group, with the active drug Aricept 5 mg (donepezil hydrochloride) from Daewoong Pharmaceuticals administered to the active control group, for 12 weeks.

Conditions

Mild Alzheimer Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Aricept 5 mg

Aricept 5 mg + Placebo of PM012 eight tablets, daily during 12 weeks (oral)

Group Type: ACTIVE_COMPARATOR

PM012 Placebo

Intervention Type: DRUG

PM012 tablet placebo

Donepezil

Intervention Type: DRUG

Aricept 5 mg (donepezil hydrochloride) drug

PM012 2,600 mg

PM012 2,600 mg + Placebo of PM012 four tablets +Placebo of Aricept one tablet, daily during 12 weeks (oral)

Group Type: EXPERIMENTAL

PM012

Intervention Type: DRUG

PM012 650 mg tablet drug

PM012 Placebo

Intervention Type: DRUG

PM012 tablet placebo

Donepezil placebo

Intervention Type: DRUG

Aricept 5 mg (donepezil hydrochloride) placebo

PM012 3,900 mg

PM012 3,900 mg + Placebo of PM012 two tablets +Placebo of Aricept one tablet, daily during 12 weeks (oral)

Group Type: EXPERIMENTAL

PM012

Intervention Type: DRUG

PM012 650 mg tablet drug

PM012 Placebo

Intervention Type: DRUG

PM012 tablet placebo

Donepezil placebo

Intervention Type: DRUG

Aricept 5 mg (donepezil hydrochloride) placebo

PM012 5,200 mg

PM012 5,200 mg + Placebo of Aricept one tablet, daily during 12 weeks (oral)

Group Type: EXPERIMENTAL

PM012

Intervention Type: DRUG

PM012 650 mg tablet drug

Donepezil placebo

Intervention Type: DRUG

Aricept 5 mg (donepezil hydrochloride) placebo

Interventions

PM012

PM012 650 mg tablet drug

Intervention Type: DRUG

PM012 Placebo

PM012 tablet placebo

Intervention Type: DRUG

Donepezil

Aricept 5 mg (donepezil hydrochloride) drug

Intervention Type: DRUG

Donepezil placebo

Aricept 5 mg (donepezil hydrochloride) placebo

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• 1) Male and female patients aged ≥ 50 and ≤ 85 years.
• 2) Patients clinically diagnosed as probable Alzheimer's disease based on DSM-IV and NINCDS-ADRDA criteria.
• 3) Patients between MMSE score of 20~26 at screening visit.
• 4) Patients with Global CDR score of 0.5 or 1 at the screening visit.
• 5) Patients administered with donepezil 5㎎ stably for over 3 months or who have never been administered donepezil.
• 6) Patients who can perform cognitive or other necessary tests.
• 7) Patients who have a caretaker who can accompany the patient for all clinical visits and for the primary efficacy evaluation (a caretaker is a family member or someone trustworthy who provides care for daily activities, spending more than 8 hours per week with patients).
• 8) Patients who have consented to participate in medically acceptable contraception*

• Effective contraception methods: Infertility surgery of the patient or his/her spouse (vasectomy, tubal ligation), placement of an intrauterine contraceptive device, double barrier method (concomitant use of spermicides and condoms, and contraceptive diaphragms, vaginal sponges, or cervical caps). Oral contraceptives and intermittent celibacy (absolute celibacy is allowed) are not acknowledged as effective contraceptive methods.
• 9) Patients who have signed the informed consent on his/her own will

Exclusion Criteria

• 1) Patients with hypersensitivity to the investigational product or components contained in the investigational product.
• 2) Patients with hypersensitivity to piperidine derivatives.
• 3) Patients with possible, probable or definite vascular dementia according to the NINDS-AIREN criteria.
• 4) History (cerebrovascular disease, structural or developmental malformations, epilepsy, contagious, degenerative, or infectious/demyelinating CNS status) and/or evidence (CT or MRI results performed at screening or within 12 months) of other CNS diseases as the major cause of dementia.
• 5) Patients who are illiterate.
• 6) Patients with severe hearing or visual disabilities so that efficacy assessment is impossible.
• 7) Abnormal test results for vitamin B12, serologic testing for syphilis, or thyroid stimulating hormone (TSH) that may have contributed to or may be the cause of patient's dementia.
• 8) Patients with a history of significant psychiatric disease such as schizophrenia or bipolar disorder that may interfere with participation in the trial as viewed by the investigator, or patients with current major depression disorder (Short Form GDS ≥ 7) (However, patients who depressed due to Alzheimer's disease can participate in this trial by the investigator).
• 9) Patients with genetic disorders such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.
• 10) Patients with a history of known or suspected seizure including febrile seizure, or recent history of loss of consciousness or a history of significant head trauma with loss of consciousness.
• 11) Patients with gastrointestinal, endocrinological, or cardiovascular disorders that is not controlled by diet or drugs.
• 12) Patients with cardiac diseases such as myocardial infarction, valvular heart disease, or arrhythmia within 3 months prior to screening.
• 13) Patients with asthma or obstructive pulmonary diseases that is not controlled by drugs.
• 14) Patients with extrapyramidal disorders (Parkinson's disease, Parkinsonism, etc).
• 15) Patients with dementia due to Creutzfeldt-Jakob disease, Pick's disease, or Huntington's disease.
• 16) Patients with uncontrolled diabetes (HbA1c > 8.0%) or insulin dependent diabetes.
• 17) Patients with a history of alcohol or other substance abuse.
• 18) Patients with hypertension with systolic pressure over 165mmHg or diastolic pressure over 96mmHg.
• 19) Patients with severe renal dysfunction (Serum creatinine over 2.0㎎/dl).
• 20) Patients with severe liver dysfunction (ALT, AST, total bilirubin more than 2.5-fold the upper normal limit).
• 21) Patient who has been administered drugs that Dementia drugs(Donepezil, Galantamine, Memantine, Rivastigmine tartrate) within 3 months prior to screening (However, patients who have been administered donepezil 5mg stably for over 3 months are excluded).
• 22) Patient who has required to take restricted drugs other than investigational products during the clinical trial period.
• 23) patient who has unabled to take concomitant drugs during the clinical trial period under the following conditions : It was taken without dose change 2 months before randomization, and was taken without dose change during the clinical trial period (except for drugs allowed to be taken as needed).
• 24) Patients with a history of clinically significant drug hypersensitivity reaction.
• 25) Patients who have been administered investigational products from another clinical trial within 3 months prior to participation in this trial.
• 26) Patients who are deemed unfit to participate in this trial by the investigator.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

LSK Global Pharma Services Co. Ltd.

UNKNOWN

Sponsor Role: collaborator

Mediforum Ltd., Co.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Mediforum

Seoul, Seongdon-gu, South Korea

Site Status: RECRUITING

Countries

South Korea

Central Contacts

Dai Won Yoo

Role: CONTACT

stiger9189@gmediforum.com

+82.10.9412.9189

Facility Contacts

Dai Won Yoo

Role: primary

stiger9189@gmediforum.com

+82.10.9412.9189

Related Links

https://pubmed.ncbi.nlm.nih.gov/22458507/

Safety and efficacy assessment of standardized herbal formula PM012

https://pubmed.ncbi.nlm.nih.gov/26446019/

Standardized Herbal Formula PM012 Decreases Cognitive Impairment and Promotes Neurogenesis in the 3xTg AD Mouse Model of Alzheimer's Disease

Other Identifiers

MFDS-31834

Identifier Type: -

Identifier Source: org_study_id